<DOC>
	<DOCNO>NCT02790918</DOCNO>
	<brief_summary>In study , study team aim ) evaluate accuracy 3D IVS curvedness prediction RV systolic pressure ( RVSP ) , mean pulmonary artery pressure ( mPAP ) pulmonary vascular resistance ( PVR ) RHC ; ii ) evaluate usefulness 3D IVS curvedness predict response vasodilator challenge RHC , patient clinically suspect known primary PH .</brief_summary>
	<brief_title>Diagnosis Pulmonary Hypertension Using Cardiac Magnetic Resonance Images</brief_title>
	<detailed_description>1 ) Pulmonary hypertension Pulmonary hypertension ( PH ) manifest increase mean pulmonary artery pressure ( i.e. , mPAP ≥ 25 mmHg ) rest right heart catheterization ( RHC ) ( Badesch 2009 ) . It complex multidisciplinary disorder causing restrict flow pulmonary arterial circulation due increase pulmonary vascular resistance ( PVR ) . It classify five group ( Simonneau et al 2004 ) : Group I - Idiopathic PAH , Familial PAH , PAH associate collagen vascular disease et al ; Group II - PH leave heart disease ; Group III - PH associate lung disease and/or hypoxemia ; Group IV - PH due chronic thrombotic and/or embolic disease ; Group V - miscellaneous cause PH . The prognosis PH poor . The National Institutes Health ( NIH ) Registry follow 194 patient IPAH enrol 32 clinical center 1981 1985 ( D'Alonzo et al 1991 ) . The reported median survival rate 68 % , 48 % 34 % . Similar result report Japan , India Mexico . Right heart catheterization ( RHC ) current reference standard diagnose PH ( Galie et al 2009 ; McLaughlin et al 2009 ) , accord ACCF/AHA expert consensus ( McLaughlin et al 2009 ) ESC/ERS guideline ( Galie et al 2009 ) . Three hemodynamic measurement essential RHC : right ventricular systolic pressure ( RVSP ) , mean pulmonary artery pressure ( mPAP ) pulmonary vascular resistance ( PVR ) . Further , patient PH undergo RHC ass clinical response vasodilator challenge order guide therapy . It help identify patient good prognosis patient could potentially benefit treatment calcium channel blocker . A positive acute response define reduction pulmonary artery pressure ≥10mmHg ≤40mmHg . Although RHC play pivotal role PH diagnosis , invasive without inherent risk ( Hoeper et al 2006 ) . For reason , development noninvasive alternative RHC diagnosis PH paramount . Noninvasive diagnosis PH prediction response vasodilator challenge clinically need . Several noninvasive method diagnosis PH propound , common Doppler echocardiography . While routinely used estimate pulmonary arterial pressure , Doppler measurement tricuspid regurgitation jet peak velocity inherent limitation : ( ) reliance visualization tricuspid regurgitant jet always detectable , ( ii ) fact peak velocity jet may difficult measure presence severe tricuspid regurgitation , ( iii ) need adequate acoustic window ( Hinderliter et al 2003 ; Hachulla et al 2005 ) . Furthermore , recently emphasize ERS/ESC guideline ( Galie et al 2009 ) , estimation mPAP PVR must integral part complete cardiac echocardiographic examination . It long recognize systolic flatten abnormal motion inter-ventricular septum ( IVS ) , either echocardiography ( King et al 1983 ; Reisner et al 1994 ; Ricciardi et al 1999 ) cine CMR image ( Roeleveld et al 2005 ; Dellegrottaglie et al 2007 ; Alunni et al 2010 ) , sign increase pulmonary arterial pressure . However , study either qualitative limit 2D assessment , rely analysis subjective selection image plane cardiac cycle phase . In last 10 year , despite advance biomedical engineering computational approach , rigorous study undertake study relationship quantitative 3D IVS shape PH . It well document RV dysfunction 6-min walk test ( 6MWT ) associate increase risk mortality PH ( van Wolfersen 2007 ) . Study team recently develop new method assessment RV function term area strain , integrate radial , circumferential longitudinal deformation ( Zhong et al 2012 ) . Therefore , also investigate relationship RV area strain exercise capacity PH .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Signed informed consent prior initiation study mandate procedure Age 16 year . Patient clinically suspect known primary PH belong one Updated Dana Point Clinical Classification Groups ( IIV ) No known history pulmonary hypertension Contraindication MR examination : Cardiac pacemaker Brain aneurysm clip Electronic implant prosthesis Eye metal foreign body injury Severe claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>MRI</keyword>
</DOC>